Business- Page 72

Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and molecular profiling

Following $1.03 million in completed annualized cost reductions, Polar targets approximately $2 million in total annualized savings, inclusive of Phase 1 of its Restructuring, while positioning operations to support scalable revenue growth

– Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + mGnP, as

Third quarter net sales of $7.9 billion, an increase of 10.4% Third quarter net income of $318 million, a decrease of 1.2% Third quarter Adjusted EBITDA1 of $1.0 billion, an increase of

– Quarterly Revenue of $195.3 million – – Income from Operations of $29.0 million – – Net Income of $17.9 million – – Adjusted EBITDA1 of $39.8 million – – Backlog and

~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study

— Multiple New Business Wins Continue to Strengthen Growing Pipeline — CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal

Net income: $185.7 million for Q3 2026 $459.9 million for 9M 2026 Earnings per common unit: $6.42 for Q3 2026 $15.83 for 9M 2026 Net cash from operating activities: $235.4 million for

SPOKANE, Wash., Nov. 04, 2026 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today reported the following results for the third quarter of 2026 and the nine months ended Sept. 30, 2026 as